Idiopathic Purpura Fulminans Associated With Anti-PS Antibodies in Children
Sponsor
University Hospital, Montpellier (Other)
Overall Status
Completed
CT.gov ID
NCT04845113
Collaborator
(none)
200
1
6.9
28.9
Study Details
Study Description
Brief Summary
Idiopathic purpura fulminans by anti-protein S antibody is a very rare but potentially extremely serious entity. The data in the literature are poor with only isolated report boxes and a single series of less than 10 boxes. The creation of a larger series of cases would make it possible to better understand this pathology and to offer assistance in diagnosis and management.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
200 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Idiopathic Purpura Fulminans Associated With Anti-PS Antibodies in Children: a French Multicenter Retrospective Study
Actual Study Start Date
:
Jan 1, 2021
Actual Primary Completion Date
:
Jul 1, 2021
Actual Study Completion Date
:
Jul 31, 2021
Outcome Measures
Primary Outcome Measures
- Rate of anti-protein S antibody [1 day]
Rate of anti-protein S antibody
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion criteria:
-
diagnostic of idiopathic purpura fulminans
-
Acquired protein S deficiency
Exclusion criteria:
- Other infecious purpura diagnosis
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Uhmontpellier | Montpellier | France | 34295 |
Sponsors and Collaborators
- University Hospital, Montpellier
Investigators
- Study Director: Alexandre THERON, University Hospital, Montpellier
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
University Hospital, Montpellier
ClinicalTrials.gov Identifier:
NCT04845113
Other Study ID Numbers:
- RECHMPL21_0234
First Posted:
Apr 14, 2021
Last Update Posted:
Oct 25, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Montpellier
Additional relevant MeSH terms: